A post-hoc analysis linked “physical differences” in two lots of Nektar’s drug to lower efficacy when given in combination with Bristol-Myers Squibb’s Opdivo. Nektar’s share price tumbled following the update.
Nektar Therapeutics has blamed manufacturing quality problems for falling response rates in a study of patients receiving its immuno-oncology drug bempegaldesleukin.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.
Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
